For roughly one in five adults, cardiovascular risk is quietly elevated by a factor that standard lipid panels often ignore and that no approved drug can yet specifically target. Lipoprotein(a) sits at the intersection of genetics, thrombosis, and atherosclerosis in a way that challenges the dominant LDL-centric model of heart disease prevention — and a new clinical review in the European Heart Journal Supplements consolidates what practitioners and patients need to understand right now.
Lp(a) is structurally an LDL-like particle carrying apolipoprotein B100, but its distinguishing feature is a covalent bond to apolipoprotein(a), encoded by the LPA gene. Polymorphisms in this gene regulate apo(a) isoform size and hepatic synthesis rates, making plasma Lp(a) concentrations roughly 80–90% heritable — largely unresponsive to lifestyle modification. Beyond LDL-equivalent atherogenicity, Lp(a) carries oxidized phospholipids and has structural homology with plasminogen, conferring both pro-inflammatory and antifibrinolytic (prothrombotic) properties that amplify cardiovascular and aortic valve disease risk independently of LDL levels.
In the absence of an approved Lp(a)-specific therapy, current ESC/EAS guidance defaults to aggressive LDL lowering — high-intensity statins, ezetimibe, and PCSK9 inhibitors — as an indirect risk-mitigation strategy, since reducing competing lipid burden lowers absolute event risk even if Lp(a) itself remains unchanged. Lipoprotein apheresis can acutely reduce Lp(a) by 60–70% but remains a niche intervention given its logistical burden. The emerging pipeline — antisense oligonucleotides (pelacarsen) and siRNA agents (olpasiran, zerlasirsen) — can suppress Lp(a) by over 90% and are currently in large Phase III cardiovascular outcomes trials. This review is appropriately framed as a transitional document: it codifies the evidence gap that the next generation of trials is designed to close. For high-risk adults, Lp(a) measurement is increasingly considered a one-time, lifetime test that could reframe entire prevention strategies once specific therapies receive approval.
